Automated Insulin for Management of Intrapartum Glycemia
Key facts
- Where
- Los Angeles, San Diego, and San Francisco, United StatesSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT06883344, who can take part
Where in United States
- University of California, Los AngelesLos Angeles, United StatesTaking people
- University of California San DiegoSan Diego, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT06883344
- Record updated
- 13 July 2026
- Original description
The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer areRead full original descriptionShow less
Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial
The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are
* What are the neonatal glycemic outcomes with use of AID systems during labor/delivery? * Do patients report higher birth satisfaction with use of AID systems during labor/delivery? * Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor/delivery?
Researchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor/delivery) by randomly assigning participants to one or the other.
Inclusion: Currently pregnant at ≥ 34 weeks; Known diagnosis of type 1 diabetes ≥ 1 year; Use of commercially available AID system since at least 28 weeks gestation; Singleton pregnancy; English- or Spanish-speaking.
Exclusion: Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare; Use of medications known to interfere with glucose metabolism; Multifetal gestation; Planned cesarean delivery; Intrauterine fetal demise.